Indivior Plc
INDV
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.05B
Close$
$-1.19
103% downside
Current Fair Value
103% downsideOvervalued by 103% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.05 Billion |
|---|---|
| Enterprise Value | $4.94 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.68 |
| Beta | 1.15 |
| Outstanding Shares | 125,352,000 |
Return
| Return on Equity | -175.00% |
|---|---|
| Return on Assets | 21.05% |
| Return on Invested Capital | 81.10% |
Valuation & Multiples
| P/E Ratio | 20.15 |
|---|---|
| PEG | 22.55 |
| Price to Sales | 4.02 |
| Price to Book Ratio | -20.12 |
| Enterprise Value to Revenue | 3.83 |
| Enterprise Value to EBIT | 14.58 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 30, 2026
EPS Estimate
$0.64
Average shareholder expectationRevenue Estimate
$272.84 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$0.88
Average shareholder expectationRevenue Estimate
$306.55 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 87.30% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.57%▼ 100.61% |
|---|---|
| Total Invested | $80.60M▼ 97.93% |
| Investors Holding | 11▼ 285.00% |
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...